OneDigital Investment Advisors LLC Invests $400,000 in TransMedics Group, Inc. $TMDX

OneDigital Investment Advisors LLC bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 6,020 shares of the company’s stock, valued at approximately $400,000.

Several other hedge funds also recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in TransMedics Group by 11.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock worth $119,997,000 after acquiring an additional 113,817 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of TransMedics Group by 50.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after acquiring an additional 322,353 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of TransMedics Group by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock valued at $99,339,000 after acquiring an additional 2,903 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of TransMedics Group by 54.2% during the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after purchasing an additional 223,409 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of TransMedics Group by 43.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock worth $69,338,000 after purchasing an additional 171,810 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director owned 16,642 shares in the company, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on TMDX. Piper Sandler reissued an “overweight” rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Wall Street Zen lowered TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Oppenheimer cut TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Stifel Nicolaus lifted their price objective on TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, June 18th. Finally, UBS Group reduced their target price on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 5th. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $124.18.

TransMedics Group Trading Up 3.6%

TMDX opened at $93.97 on Thursday. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. TransMedics Group, Inc. has a 52 week low of $60.10 and a 52 week high of $156.00. The stock has a market cap of $3.25 billion, a PE ratio of 24.16 and a beta of 1.90. The business has a 50 day moving average of $76.71 and a 200-day moving average of $95.63.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). The firm had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.TransMedics Group’s revenue for the quarter was up 20.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.92 earnings per share. Equities research analysts predict that TransMedics Group, Inc. will post 1.47 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.